首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

1593536

CAR-T细胞疗法市场规模、份额和成长分析（按产品、按目标、按适应症、按人口统计、按最终用户、按地区）：产业预测（2024-2031）

CAR T-Cell Therapy Market Size, Share, Growth Analysis, By Product (Yescarta, Kymriah), By Target (CD19, BCMA), By Indication, By Demographic, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月14日 | 出版商:

SkyQuest | 英文 197 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球CAR-T细胞治疗市场规模估值为52亿美元，从2023年的72.7亿美元增长到2031年的1060.6亿美元，预计在预测期内（2024-2031年）将持续增长。复合年增长率为39.80%）。

预计全球癌症流行将在未来几年显着推动 CAR-T 细胞治疗的需求。由于细胞研究投资的增加和基因工程技术的进步，CAR-T细胞治疗市场预计将出现强劲成长。对个人化医疗的日益关注可能会进一步增加对 CAR-T 细胞疗法的需求，特别是对于血癌，这将为该领域的服务提供者创造新的商机。此外，针对各种慢性疾病的创新 CAR-T 细胞疗法的核准频率不断增加，支持了全球市场扩张的潜力。然而，也存在一些挑战，例如治疗成本上升、对安全性和副作用的担忧以及患者接触机会有限等。解决这些阻碍因素对于最大限度地发挥 CAR T 细胞疗法的潜力并确保其覆盖更广泛的患者群体至关重要。随着这种情况的发展，市场相关人员将需要考虑如何克服这些挑战，同时利用技术进步和肿瘤学领域日益增长的未满足的医疗需求带来的新机会。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲 (MEA)
- 波湾合作理事会(GCC) 国家
- 南非
- 其他中东/非洲

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

诺华公司（瑞士）
强生公司（美国）
JW (Cayman) Therapeutics Co. Ltd.（开曼群岛）
免疫过继性细胞疗法私人有限公司（Immunoact）（印度）
Carsgen Therapeutics Holdings Limited (中国)
IASO生物治疗（中国）
广州百基因科技有限公司（七喜集团股份有限公司）（中国）
Cartesian Therapeutics, Inc.（美国）
Autolus Therapeutics（英国）
同种异体疗法（美国）
Crispr Therapeutics（瑞士）
乌根（美国）
Sangamo Therapeutics, Inc.（美国）
蓝鸟生物公司（美国）
TCR2 Therapeutics Inc.（美国）
Genocea Biosciences, Inc.（美国）
Blairex Laboratories, Inc.（美国）
Medigene AG（德国）
Athenex, Inc.（美国）
Zymeworks Inc.（加拿大）
Regenxbio Inc.（美国）

简介目录

Product Code: SQMIG35H2300

Global CAR T-Cell Therapy Market size was valued at USD 5.2 billion in 2022 and is poised to grow from USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of 39.80% during the forecast period (2024-2031).

The global cancer epidemic is anticipated to significantly drive the demand for CAR T-cell therapy in the upcoming years. With rising investments in cell research and advancements in genetic engineering technologies, the CAR T-cell therapy market is poised for robust growth. The increasing emphasis on personalized medicine is likely to further propel demand for CAR T-cell treatments, particularly in addressing blood cancer indications, which presents new opportunities for service providers in this field. Additionally, the growing frequency of approvals for innovative CAR T-cell therapies aimed at various chronic conditions underscores the expanding market potential on a global scale. However, the market faces challenges, including the high costs associated with treatment, concerns regarding procedural safety and potential side effects, as well as limited accessibility for patients. Addressing these restraints will be critical for unlocking the full potential of CAR T-cell therapies and ensuring they reach broader patient populations. As the landscape evolves, stakeholders in the CAR T-cell therapy market must navigate these challenges while capitalizing on emerging opportunities presented by technological advancements and increasing unmet medical needs in oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Car T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Car T-Cell Therapy Market Segmental Analysis

Global CAR T-Cell Therapy Market is segmented by Product, Target, Indication, Demographic, End User, and region. Based on Product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi, and Other Products. Based on Target, the market is segmented into CD19, BCMA, and Other Targets. Based on Indication, the market is segmented into Multiple Myeloma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia, and Other Indications. Based on Demographic, the market is segmented into Adults, and Pediatrics. Based on End User, the market is segmented into Hospitals, Specialty Centers, and Long-Term Care Facilities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Car T-Cell Therapy Market

The surge in personalized medicine is a significant market driver for the Global CAR T-Cell Therapy market, as it aligns closely with the growing demand for tailored healthcare solutions. As patients increasingly seek individualized treatment options, the ability of CAR T-cell therapy to be customized for each patient's unique tumor characteristics enhances its efficacy and appeal. This personalization not only improves therapeutic outcomes but also fosters patient engagement and adherence to treatment protocols. Consequently, the broader acceptance and integration of personalized medicine within oncology are expected to propel the CAR T-cell therapy market, leading to innovative advancements and expanding clinical applications in the coming years.

Restraints in the Global Car T-Cell Therapy Market

One significant market restraint for the Global CAR T-Cell Therapy market is the lingering uncertainty surrounding the long-term safety and potential side effects associated with this innovative treatment. Despite rigorous testing, concerns about adverse reactions, such as cytokine release syndrome and neurotoxicity, can lead to apprehension among patients and healthcare providers, ultimately hindering widespread adoption. Additionally, the complexity of administering CAR T-cell therapy and the requirement for specialized medical personnel and infrastructure further complicate its integration into standard cancer treatment protocols. This combination of safety concerns and logistical challenges may slow the growth of the CAR T-cell therapy market over the forecast period.

Market Trends of the Global Car T-Cell Therapy Market

The global CAR T-cell therapy market is witnessing a significant trend towards the development of allogeneic therapies, which utilize genetically modified T-cells derived from healthy donors rather than the patient's own cells. This innovation is driven by the potential for off-the-shelf treatment options that can provide quicker, more accessible solutions for patients with hematologic malignancies and solid tumors. With advancements in gene-editing technologies and the growing emphasis on reducing manufacturing complexities and costs, allogeneic CAR T-cell therapies are expected to gain traction, fostering increased investment and collaboration within the biopharmaceutical landscape. This shift promises to enhance patient outcomes while expanding market reach.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Value Chain Analysis
Technology Analysis
Patent Analysis
Pricing Analysis
Regulatory Landscape
Customer & Buying Criteria Analysis

Car T-Cell Therapy Market by Product

Market Overview
Yescarta
Kymriah
Carvykti
Abecma
Tecartus
Breyanzi
Other Products

Car T-Cell Therapy Market by Target

Market Overview
CD19
BCMA
Other Targets

Car T-Cell Therapy Market by Indication

Market Overview
Multiple Myeloma
B-Cell Lymphoma
Acute Lymphoblastic Leukemia
Other Indications

Car T-Cell Therapy Market by Demographic

Market Overview
Adults
Pediatrics

Car T-Cell Therapy Market by End User

Market Overview
Hospitals
Specialty Centers
Long-Term Care Facilities

Car T-Cell Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JW (Cayman) Therapeutics Co. Ltd. (Cayman Islands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunoadoptive Cell Therapy Private Limited (Immunoact) (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carsgen Therapeutics Holdings Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IASO Biotherapeutics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Bio-Gene Technology Co., Ltd (Hedy Group Co., Ltd.) (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cartesian Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Autolus Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allogene Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Crispr Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wugen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TCR2 Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genocea Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blairex Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medigene AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athenex, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments